Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
l�ll
Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials Haggerty CL; Ness RBClin Infect Dis 2007[Apr]; 44 (7): 953-60Treatment of pelvic inflammatory disease (PID) should provide high rates of clinical and microbiological cure for a range of pathogens and should ultimately prevent reproductive morbidity. Between 1992 and 2006, 5 randomized clinical trials of moxifloxacin (1 trial), ofloxacin (1 trial), clindamycin-ciprofloxacin (1 trial), and azithromycin (2 trials) treatment among women with mild to moderate PID were found to have clinical cure rates of 90%-97%. Trials of ofloxacin and clindamycin-ciprofloxacin reported rates of cure of Neisseria gonorrhoeae and Chlamydia trachomatis infection of 100%, although microbiological cure data for other pathogens were not presented. One azithromycin trial reported a 98% eradication of C. trachomatis, N. gonorrhoeae, Mycoplasma hominis, and anaerobes. Moxifloxacin exhibited high eradication rates for N. gonorrhoeae, C. trachomatis, M. hominis, Mycobacterium genitalium, and gram-negative anaerobes. Clinical cure rates from 2 doxycycline-metronidazole trials were low (35% and 55%). Although a handful of studies have shown that monotherapies for PID achieve high rates of clinical cure, the efficacy of these regimens in treating anaerobic PID and in preventing adverse reproductive sequelae is not fully elucidated.|Anti-Bacterial Agents/*administration & dosage[MESH]|Aza Compounds/administration & dosage[MESH]|Azithromycin/administration & dosage[MESH]|Ciprofloxacin/administration & dosage[MESH]|Clindamycin/administration & dosage[MESH]|Dose-Response Relationship, Drug[MESH]|Drug Administration Schedule[MESH]|Drug Resistance, Microbial[MESH]|Female[MESH]|Fluoroquinolones[MESH]|Follow-Up Studies[MESH]|Humans[MESH]|Microbial Sensitivity Tests[MESH]|Moxifloxacin[MESH]|Ofloxacin/administration & dosage[MESH]|Pelvic Inflammatory Disease/*drug therapy/*microbiology[MESH]|Quinolines/administration & dosage[MESH]|Randomized Controlled Trials as Topic[MESH]|Risk Assessment[MESH]|Severity of Illness Index[MESH]|Treatment Outcome[MESH] |